华泰联合证券有限责任公司 关于北京英诺特生物技术股份有限公司 2024 年度持续督导跟踪报告 | 保荐机构名称：华泰联合证券有限责任公司 | 被保荐公司名称：北京英诺特生物技术股份有限 | | --- | --- | | | 公司 | | 保荐代表人姓名：丁明明 | 联系电话：010-56839300 | | 保荐代表人姓名：郑明欣 | 联系电话：010-56839300 | 根据《证券法》《证券发行上市保荐业务管理办法》和《上海证券交易所科创 板股票上市规则》等有关法律、法规的规定，华泰联合证券有限责任公司（以下简 称"华泰联合"或"保荐机构"）作为北京英诺特生物技术股份有限公司（以下简称 "英诺特"或"公司"）首次公开发行股票的保荐机构，对英诺特进行持续督导，并出 具 2024 年度（以下简称"本报告期"或"报告期"）持续督导跟踪报告： 一、持续督导工作情况 | 序号 | 项目 | 持续督导工作情况 | | --- | --- | --- | | | 建立健全并有效执行持续督导工作制度， | 保荐机构已制定并严格执行持续督导 | | 1 | 并针对具体的持续督导工作制定相应的工 | 工作制度，已根据公司的 ...

Group 1 - The A-share market saw a collective decline on May 16, while the Sci-Tech Innovation Pharmaceutical sector rebounded, with the Sci-Tech Innovation Pharmaceutical ETF (588860) rising by 0.16% [1] - Notable stocks in the sector included Maiwei Biotech-U, which increased by over 5%, along with Shouyao Holdings-U, KQ Biotech, Innotec, CanSino, and Baotai, all of which experienced gains [1] - The Sci-Tech Innovation Pharmaceutical ETF closely tracks the Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index, which selects 50 large-cap companies in biopharmaceuticals and related fields to reflect the overall performance of representative companies in the sector [1] Group 2 - According to CMB International, the optimization of centralized procurement policies in mainland China provides hospitals and enterprises with more flexibility and autonomy, benefiting leading prescription drug companies [2] - The anticipated implementation of favorable policies, such as the 2025H2 medical insurance category, is expected to accelerate industry consolidation, with the sector's valuations remaining at historical lows [2] - The recommendation is to focus on innovative drug targets with high growth potential or clear breakeven timelines after short-term sentiment stabilizes [2]

Group 1 - The core viewpoint of the article highlights that Innotech's stock closed at 31.5 yuan, down 1.25%, with a rolling PE ratio of 21.92 times and a total market capitalization of 4.298 billion yuan [1] - Innotech operates in the bioproducts industry, which has an average PE ratio of 57.79 times and a median of 38.07 times, placing Innotech at the 34th position in the industry ranking [1] - As of the first quarter of 2025, four institutions held shares in Innotech, with a total of 5.2561 million shares valued at 183 million yuan [1] Group 2 - Innotech's main business focuses on the research, production, and sales of POCT rapid diagnostic products, primarily targeting respiratory pathogen detection, while also covering areas such as reproductive health, digestive tract, and hepatitis testing [1] - The latest performance report for the first quarter of 2025 shows that Innotech achieved an operating revenue of 207 million yuan, a year-on-year decrease of 26.51%, and a net profit of 95.2897 million yuan, down 34.77%, with a gross profit margin of 83.12% [1]

北京英诺特生物技术股份有限公司 2024 年年度股东大会会议资料 证券代码：688253 证券简称：英诺特 北京英诺特生物技术股份有限公司 2024 年年度股东大会会议资料 2025 年 5 月 22 日 1 / 30 北京英诺特生物技术股份有限公司 2024 年年度股东大会会议资料 北京英诺特生物技术股份有限公司 2024 年年度股东大会会议资料目录 | 年年度股东大会会议须知 2024 3 | | --- | | 2024 年年度股东大会会议议程 5 | | 年年度股东大会会议议案 2024 7 | | 议案一：关于公司 2024 年年度报告及其摘要的议案 7 | | 议案二：关于公司 年度财务决算报告的议案 8 2024 | | 议案三：关于公司 2025 年度财务预算报告的议案 9 | | 议案四：关于 年度董事会工作报告的议案 10 2024 | | 议案五：关于 2024 年度监事会工作报告的议案 11 | | 议案六：关于公司 2024 年年度利润分配方案的议案 12 | | 议案七：关于续聘公司 2025 年度审计机构的议案 13 | | 议案八：关于 2025 年度董事薪酬方案的议案 14 ...

Financial Performance - The company achieved total operating revenue of 621.39 million, representing a year-on-year growth of 29.99% [2][5] - The net profit attributable to shareholders was 246.86 million, reflecting a year-on-year increase of 41.92% [2][5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 217.75 million, with a year-on-year growth of 48.08% [2][5] Cash Flow - The net cash flow from operating activities was 305.46 million, showing a year-on-year increase of 17.55% [5] - The net cash flow from investing activities was -63.07 million, an improvement from -429 million in the previous year [5] - The net cash flow from financing activities was -103 million, a decrease of 58.27 million year-on-year [5] Assets and Liabilities - The net assets attributable to shareholders at the end of 2024 were 1,993.39 million, an increase of 8.22% compared to the end of 2023 [1] - Total assets reached 2,212.46 million, reflecting a year-on-year growth of 7.11% [1] - Cash and cash equivalents increased by 84.86% compared to the previous year, with a rise in proportion to total assets by 5.85 percentage points [5] Company Overview - The company, Beijing Innotech Biotechnology Co., Ltd., focuses on the research, development, production, and sales of POCT rapid diagnostic products [6] - It specializes in the field of in vitro diagnostics, particularly in respiratory pathogen detection, and has developed multiple detection technologies [6] - The company has established a significant market position in respiratory pathogen detection, with products recognized by major children's hospitals [6] Research and Development - The company has built six major technology platforms, including immunochromatography and nucleic acid molecular detection [7] - R&D investment reached 97.17 million in 2024, a year-on-year increase of 82.95%, accounting for 15.64% of operating revenue [7]

一、回购股份的基本情况 证券代码：688253 证券简称：英诺特 公告编号：2025-023 北京英诺特生物技术股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/8/3 | | --- | --- | | 回购方案实施期限 | 待董事会审议通过后 个月 12 | | 预计回购金额 | 5,000万元~10,000万元 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 □用于转换公司可转债 | | 累计已回购股数 | □为维护公司价值及股东权益 211.2740万股 | | 累计已回购股数占总股本比例 | 1.5483% | | 累计已回购金额 | 7,801.24万元 | | 实际回购价格区间 | 28.62元/股~45.37元/股 | 特此公告。 北京英诺特生物技术股份有限公司董事会 2025 年 5 月 7 日 2024 年 8 月 2 日，公司召开第二届董事会第五次会议，会议审议通过了《关 于 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [2] Core Views - The company has shown significant growth in its respiratory multi-detection products, with a revenue increase of 29.99% year-on-year, reaching 621 million yuan in 2024. The net profit attributable to the parent company also increased by 41.92% to 247 million yuan [6][8] - The company is expanding its product offerings in Alzheimer's disease (AD) detection through a strategic partnership with Quanterix, leveraging advanced digital immunoassay technology for early diagnosis and screening [7][8] - The company is expected to achieve steady revenue and profit growth in the coming years, with projected revenues of 729 million yuan in 2025, 828 million yuan in 2026, and 921 million yuan in 2027, reflecting year-on-year growth rates of 17.3%, 13.6%, and 11.3% respectively [8] Financial Summary - In 2024, the company achieved a total revenue of 621 million yuan, with a year-on-year growth of 30.0%. The net profit attributable to the parent company was 247 million yuan, with a net profit growth of 41.9% [11] - The projected financials for 2025 to 2027 indicate a consistent growth trajectory, with net profits expected to reach 280 million yuan in 2025, 325 million yuan in 2026, and 390 million yuan in 2027, corresponding to growth rates of 13.5%, 15.9%, and 20.1% respectively [11] - The company's gross margin is projected to remain strong, with estimates of 80.1% in 2024, 83.8% in 2025, and gradually declining to 79.3% by 2027 [11]

Group 1 - The company achieved revenue and net profit attributable to shareholders of 621 million and 247 million yuan in 2024, representing year-on-year growth of 30.0% and 41.9%, respectively, aligning with performance expectations [1] - In Q1 2025, the company reported revenue and net profit attributable to shareholders of 207 million and 95 million yuan, showing year-on-year declines of 26.5% and 34.8%, attributed to domestic policy adjustments and high base effects from Q1 2024 [1] - The gross profit margin for 2024 was 80.1%, an increase of 4.1 percentage points year-on-year, driven by a higher proportion of revenue from high-margin conventional products [1] Group 2 - The core respiratory product series generated revenue of 607 million yuan in 2024, reflecting a year-on-year increase of 30.8%, with continued market recognition and an expanding sales network [2] - Incremental businesses, including the prenatal and other series, achieved revenues of 4.17 million, 10.36 million, and 0.16 million yuan, with year-on-year growth rates of 0.8%, 7.4%, and a decline of 70.0%, respectively [2] - The company anticipates further growth in its incremental businesses in 2025, supported by new product approvals and enhanced sales promotion efforts [2] Group 3 - The company has successfully launched multiple new products in the chemical luminescence and PCR categories, enhancing its competitive position in the IVD market [3] - The company is increasing its investment in consumer-end business, establishing independent teams across product, R&D, and marketing to adapt to new home testing scenarios [3] - By the end of 2024, the company has established a significant presence in Southeast Asia and is advancing clinical trials and regulatory submissions for IVDR and FDA products in Europe and the U.S. [3] Group 4 - The company adjusted its EPS forecasts for 2025-2027 to 1.92, 2.21, and 2.53 yuan, reflecting a downward revision of 51% and 57% for 2025 and 2026, respectively, due to short-term revenue growth disruptions from domestic policy changes [4] - The company is assigned a target price of 40.23 yuan for 2025, based on a 21x PE ratio, compared to a previous target of 58.50 yuan [4]

Investment Rating - The report does not explicitly state an investment rating for the industry, but it suggests a long-term focus on domestic innovative drugs in the oncology field and AI medical investment opportunities [3][4]. Core Insights - The pharmaceutical and biotechnology sector saw a weekly increase of 1.16%, outperforming the Wind All A index (1.15%) and the CSI 300 index (0.38%) [3][8]. - The upcoming ASCO conference is highlighted as a significant event for domestic innovative drug companies, with over 70 oral presentations and more than 10 major studies expected [3][4]. - The Ministry of Industry and Information Technology and six other departments issued a plan for the digital transformation of the pharmaceutical industry, aiming for significant advancements by 2027 and full coverage by 2030 [3][4]. Market Weekly Review - The pharmaceutical and biotechnology sector increased by 1.16% from April 21 to April 25, outperforming the Wind All A index and the CSI 300 index [3][8]. - Notable performers included medical research outsourcing (6.34%) and raw materials (4.72%), while blood products (-3.26%) and vaccines (-6.38%) continued to decline [3][9]. - Individual stock performances showed significant gains for Yong'an Pharmaceutical (31.4%), Shuyou Shen (28.4%), and Erkang Pharmaceutical (27.7%), while *ST Jiyuan (-43.2%), Nanhua Biological (-35.3%), and Shuangcheng Pharmaceutical (-27.7%) faced substantial losses [3][11]. Industry News and Key Company Announcements - On April 25, Kangfang Bio announced FDA approval for its drug Anike for the treatment of recurrent or metastatic nasopharyngeal carcinoma [12]. - The same day, Kangfang Bio also reported the approval of its PD-1/VEGF bispecific antibody for first-line treatment of specific lung cancer types [13]. - The digital transformation plan for the pharmaceutical industry aims to enhance competitiveness and quality management through AI and data integration by 2030 [3][4].

Company Overview - Innotech announced a 2024 dividend plan proposing a cash distribution of 5.6 yuan per 10 shares (including tax), totaling approximately 75.23 million yuan, which represents 30.48% of the net profit, marking the third cumulative cash distribution since the company's listing [2] - The company reported a revenue of 621 million yuan for the year, reflecting a year-on-year growth of 29.99%, and a net profit of 247 million yuan, up 41.92% year-on-year, with a basic earnings per share of 1.81 yuan and a weighted average return on equity of 12.74% [2] Dividend History - The historical dividend distribution plans since the company's listing are as follows: - 2024: 10 shares pay 5.6 yuan (total cash of 0.75 billion yuan, dividend yield of 1.52%) - 2023: 10 shares pay 4 yuan (total cash of 0.54 billion yuan, dividend yield of 1.53%) - 2022: 10 shares pay 1.66 yuan (total cash of 0.23 billion yuan, dividend yield of 0.57%) [2] Market Performance - The stock experienced a net outflow of 2.36 million yuan from major funds today, with a total net outflow of approximately 9.88 million yuan over the past five days [3] - The latest margin financing balance for the stock is 239 million yuan, which has decreased by 13.36 million yuan over the past five days, representing a decline of 5.29% [4] Industry Context - Innotech belongs to the pharmaceutical and biotechnology sector, which has seen 255 companies announce their 2024 dividend plans. The highest cash distribution was from WuXi AppTec at 7.692 billion yuan, followed by Yunnan Baiyao and Aier Eye Hospital with distributions of 2.114 billion yuan and 1.487 billion yuan, respectively [4]